So why are certain cholera strains so successful at evading phage attacks? Could this either enable or enhance the pathogen's devastating effect on human populations? One event stands out.

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.